image credit: Unsplash

Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDA

October 21, 2021

Menarini and Radius Health have gained a lead over AstraZeneca, Roche and Sanofi in the race to bring a new class of oral breast cancer drugs to market, posting phase 3 data and outlining plans to seek approvals on both sides of the Atlantic next year.

Menarini and Radius, like their larger rivals AstraZeneca, Roche and Sanofi, are pursuing the idea that oral selective estrogen receptor degraders (SERDs) can help a subset of breast cancer patients whose disease is driven by the signaling of estrogen receptors. AstraZeneca validated the approach years ago with intramuscular Faslodex, but it, along with its rivals, sees an opportunity for oral options.

Read More on FierceBiotech